Strong Revenue Growth
TriSalus reported $29.4 million in net sales for 2024, reflecting a 59.4% growth over 2023. The company also achieved a 44% revenue increase in Q4 2024 compared to Q4 2023.
Expansion of PEDD Technology
The company successfully expanded its pressure-enabled drug delivery (PEDD) technology into new clinical applications, achieving 43% growth in unique ordering accounts and a 10% increase in average units sold per account.
New HCPCS Reimbursement Code
CMS issued a new HCPCS code C8004 for simulation or mapping procedures using TriNav, effective April 1, 2025, ensuring financial support for clinicians using TriNav in Medicare treatment planning.
Gross Margin Stability
TriSalus maintained a robust gross margin profile of 85% in Q4 2024 and 86% for the full year, indicating efficient cost management.
Significant Reduction in R&D Expenses
R&D expenses decreased by 62% in Q4 2024 compared to Q4 2023 and by 41% for the full year, reflecting strategic cost management.